February, 2003
© 2000 Scott S. Emerson, M.D., Ph.D.
Session
4:
64
Case Study 1: Idarubicin in AML
Parameterization
Number and timing of analyses
Boundary shape function
Level of significance
·
Worst case: just barely continued at N= 45
·
Best case: just barely stopped at N= 65